Is there a Hong Kong version of Eltrombopag?

Eltrombopag/Eltrombopag (Eltrombopag) is a thrombopoietin receptor agonist used to treat certain types of thrombocytopenia. The indications mainly include the following two situations:

Idiopathic thrombocytopenic purpura (ITP):Eltrombopag/Eltrombopag is approved for the treatment of idiopathic thrombocytopenic purpura (ITP) in adults and children. ITPIt is an autoimmune disease characterized by the body's immune system mistakenly attacking and destroying its own platelets, resulting in a decrease in the number of platelets and an increased risk of bleeding. Eltrombopag/Eltrombopag promotes the production and release of platelets by stimulating stem cells and precursor cells in the bone marrow, thereby increasing the number of platelets and reducing the occurrence of bleeding.

Chronic liver disease-associated thrombocytopenia:Eltrombopag/Eltrombopag is also approved for the treatment of adults with chronic liver disease-associated thrombocytopenia. Chronic liver disease can cause thrombocytopenia and increase the risk of bleeding. Eltrombopag/The use of eltrombopag can help increase platelet counts, thereby reducing bleeding problems associated with liver disease.

Eltrombopag/Eltrombopag has been launched in China and is included in medical insurance. Because medical insurance policies vary from place to place, the price after reimbursement is also different. For details, please consult the local hospital pharmacy or medical insurance bureau.

OverseasEltrombopag/Eltrombopag has original drugs and generic drugs. The original drugs include the Turkish original drug and the Indian version of the original drug. The prices of the two are almost the same, about more than a thousand yuan.

There are many versions of generic drugs, including those from India, Bangladesh, and Laos. The cheaper generic drug is Eltrombopag from Everest Pharmaceuticals in Bangladesh, which costs around a few hundred yuan. Other generic drugs are around one to two thousand yuan, and the ingredients of the original drug and the generic drug are basically the same.

In these two indications, Eltrombopag/Eltrombopag is used to increase the number of platelets and improve coagulation function, thereby reducing the patient's risk of bleeding. However, it should be noted that the use of the drug should always be done under the guidance of a doctor. Doctors will develop the most appropriate treatment plan based on the patient's condition, clinical characteristics and other factors to ensure that the use of Eltrombopag is safe and effective.